The scope of this study was to study the expression of potential cancer stem cell markers CD133, CD24, and CD44, with focus on CD44 exon variants in head and neck squamous cell carcinoma, in order to find attractive molecular targets for selective cancer targeting. This evidence concerns the gene PROM1 and head and neck squamous cell carcinoma.